# A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome

> **NCT04251026** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Denali Therapeutics Inc.** · enrollment: 47 (actual)

## Conditions studied

- Mucopolysaccharidosis II

## Interventions

- **DRUG:** tividenofusp alfa

## Key facts

- **NCT ID:** NCT04251026
- **Lead sponsor:** Denali Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-16
- **Primary completion:** 2031-02
- **Final completion:** 2031-02
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04251026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04251026, "A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04251026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*